Core Insights - The company has been transitioning towards the biopharmaceutical innovation sector, leading to a significant increase in its market capitalization, reflecting the market's recognition of high-quality biopharmaceutical assets [2] - To capitalize on the growth of China's innovative drug industry, the company plans to accelerate its research and development (R&D) efforts and enhance the commercialization of innovative drug products, aiming for profitability in its biopharmaceutical innovation segment [2] - The company will also strengthen its position in functional raw materials, using profits from this segment to support R&D activities and ensure stable operational performance [2]